Search details
1.
Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.
BMC Cancer
; 16: 651, 2016 08 18.
Article
in English
| MEDLINE | ID: mdl-27538465
2.
Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.
BMC Cancer
; 15: 122, 2015 Mar 13.
Article
in English
| MEDLINE | ID: mdl-25886605
3.
B Lymphocytes Are a Predictive Marker of Eribulin Response and Overall Survival in Locally Advanced or Metastatic Breast Cancer: A Multicenter, Two-Cohort, Non-Randomized, Open-Label, Retrospective Study.
Front Oncol
; 12: 909505, 2022.
Article
in English
| MEDLINE | ID: mdl-35814376
4.
Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.
BMC Cancer
; 16: 117, 2016 Feb 17.
Article
in English
| MEDLINE | ID: mdl-26887451
5.
A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.
Genet Vaccines Ther
; 8: 7, 2010 Nov 01.
Article
in English
| MEDLINE | ID: mdl-21040569
Results
1 -
5
de 5
1
Next >
>>